NCT02834546View on ClinicalTrials.gov

Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma

CompletedOBSERVATIONAL
Enrollment

143

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
BIOLOGICAL

Sorafenib plasma concentration 4 weeks after treatment initiation

Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma

Trial Locations (5)

Unknown

Institut Bergonié, Bordeaux

CHU de Limoges, Limoges

CHU de Montpellier, Montpellier

CHU de Bordeaux, Pessac

CHU de Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT02834546 - Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter